Clinical trials
Camrelizumab clinical trials
Below are recruiting camrelizumab clinical trials, each written for real people, not researchers. We’re tracking 109 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05738434RecruitingPhase 2
Testing immunotherapy plus targeted drug with short chemo for esophagus cancer
This Phase 2 study tests whether combining camrelizumab (immunotherapy) and apatinib (a targeted drug) with short-course chemotherapy can control advanced esophageal squamous cell carcinoma. It may help by improving cancer response and slowing disease growth if you’re eligible and haven’t had prior whole-body (systemic) anti-cancer treatment.
Zhengzhou, HenanAges 18–75 - NCT06172205RecruitingPhase 3
Two ways to give chemo plus immunotherapy for advanced liver cancer
This study tests whether a combination of chemotherapy (FOLFOX) plus two immunotherapy drugs (Camrelizumab and Apatinib) works better when given directly into the liver artery (HAIC) versus through a vein. It's for people with advanced liver cancer who haven't had other treatments yet.
Guangzhou, GuangdongAges 18–75 - NCT06485466RecruitingPhase 3
TACE plus Camrelizumab and Apatinib for liver cancer that can't be removed by surgery
This trial tests combining a liver-directed treatment (TACE) with two medications (Camrelizumab and Apatinib) to see if it works better for people with liver cancer that cannot be surgically removed. It is for people who have not had any previous treatment for their cancer.
Chengdu, SichuanAges 18–80 - NCT05789043RecruitingPhase 3
Test of immunotherapy plus pills and chemotherapy for advanced melanoma
This Phase 3 trial tests camrelizumab (an immune-boosting medicine) combined with apatinib (a targeted pill) and temozolomide (chemotherapy) as first treatment for advanced acral melanoma. It may help shrink the cancer and improve outcomes compared with other standard first-line options.
BeijingAges 18 years+ - NCT06438627RecruitingPhase 3
New triple therapy vs standard for advanced nasopharyngeal cancer
This trial tests a new combination of three drugs (TPC, apatinib, and camrelizumab) against the standard two-drug regimen (GP plus camrelizumab) for people with high-risk nasopharyngeal carcinoma that has spread to neck lymph nodes. The goal is to see if the three-drug combination works better and is safe.
Guangzhou, GuangdongAges 18–65 - NCT06669611RecruitingPhase 3
Comparing two drug combos for advanced nasopharyngeal cancer
This trial tests whether a new drug combination (Nab-Paclitaxel with Camrelizumab) works better than the standard GP chemotherapy plus Camrelizumab for people whose nasopharyngeal cancer has come back or spread. The goal is to find a more effective treatment option.
Guangzhou, GuangdongAges 18 years+ - NCT07267806RecruitingPhase 3
Camrelizumab and Apatinib with or without chemo for advanced liver cancer
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
Guangzhou, GuangdongAges 18 years+ - NCT04944914RecruitingPhase 3
Camrelizumab with targeted radiation for limited nasopharyngeal cancer spread
This trial tests whether combining camrelizumab (an immune medicine) with stereotactic body radiotherapy (high-precision radiation) works better than camrelizumab alone. It’s for people whose nasopharyngeal cancer has spread to a small number of spots in the body and may help control those metastases longer.
Guangzhou, GuangdongAges 18–70 - NCT05139095RecruitingPhase 2
Camrelizumab plus apatinib for high-risk pregnancy tumor
This Phase 2 trial studies whether combining camrelizumab (an immune medicine) with apatinib (a medicine that blocks blood-vessel growth) can improve treatment for women with high-risk gestational trophoblastic neoplasia (GTN) that is very high-risk, or has returned or resisted chemotherapy. It may help shrink the tumor and reduce the chance it comes back by using two different approaches together.
BeijingAges 18–60 - NCT05512481RecruitingPhase 2
Study combination treatment before surgery for high-risk acral melanoma
This Phase 2 trial tests three medicines given before surgery for people with high-risk acral melanoma (a skin cancer type). It aims to shrink or control the cancer earlier and see how well the treatment works and is tolerated.
Beijing, Beijing MunicipalityAges 18–75 - NCT05999149RecruitingPhase 3
Famitinib plus chemo and immunotherapy before breast cancer surgery
This trial tests whether adding a targeted therapy pill (famitinib) to standard chemo plus an immunotherapy (camrelizumab) can shrink triple negative breast cancer before surgery. It may help people with earlier-stage disease who have not had certain prior treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06901622Enrolling by invitationPhase 2
Testing a combination of drugs for advanced gallbladder and bile duct cancer
This trial tests whether adding a targeted therapy (anlotinib) to standard chemo plus an immunotherapy (camrelizumab) is more effective than chemo plus immunotherapy alone for advanced gallbladder or bile duct cancers that cannot be removed by surgery.
ZhengzhouAges 18–75 - NCT06423170RecruitingPhase 2
Camrelizumab plus chemo for unresectable gallbladder cancer
This trial tests a combination of the immunotherapy drug camrelizumab with two chemotherapy drugs (gemcitabine and oxaliplatin, known as GEMOX) for people with gallbladder cancer that cannot be surgically removed. It aims to see if this treatment can help shrink the tumor and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06163729RecruitingPhase 2
Testing camrelizumab plus chemo and radiation before/after surgery for stomach-esophagus cancer
This trial tests combining the immunotherapy drug camrelizumab with chemotherapy and radiation before and after surgery for a specific type of stomach-esophagus cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18–80 - NCT05738616RecruitingPhase 3
Testing lenvatinib plus TACE and immunotherapy before liver surgery
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
Chengdu, SichuanAges 18–75 - NCT05043688RecruitingPhase 3
Camrelizumab with chemo before surgery versus chemo-radiation
This Phase 3 trial compares two ways of treating resectable esophageal squamous cell cancer: (1) camrelizumab plus chemotherapy before surgery versus (2) chemo-radiation. It aims to see whether adding camrelizumab before surgery can improve outcomes for people who are planned to have their tumor surgically removed.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04070040RecruitingPhase 2
Camrelizumab for returning brain lymphoma after prior treatment
This trial studies camrelizumab (an immune medicine) for primary CNS lymphoma that has come back after standard treatment. It aims to shrink the lymphoma seen on MRI and help control the disease with a new immune-based approach.
BeijingAges 18 years+ - NCT04888429RecruitingPhase 2
Check immunotherapy plus targeted pills for advanced lung sarcomatoid cancer
This Phase 2 trial tests two medicines (an immunotherapy drug and a targeted pill) to treat advanced or metastatic pulmonary sarcomatoid carcinoma. It may help shrink tumors and control the cancer, and it also collects tumor samples to study biomarkers.
Xiamen, FujianAges 18–75 - NCT07238881RecruitingPhase 2
Dalpiciclib plus camrelizumab for liver cancer after immunotherapy
This trial tests two drugs, dalpiciclib and camrelizumab, for people with advanced liver cancer (stage C) whose cancer has grown despite previous immunotherapy. The goal is to see if this combination can shrink or slow the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06711471RecruitingPhase 2
Combination therapy for advanced stomach cancer after prior treatments
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05761470RecruitingPhase 2
Test before-surgery cancer treatment for breast tumors with DNA repair gene changes
This trial tests a combination of medications given before surgery (neoadjuvant therapy) for early breast cancer. It is designed for tumors with certain “DNA repair” gene mutations and aims to improve treatment results while shrinking or controlling the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06607107RecruitingPhase 2
Combination therapy for liver cancer beyond Milan criteria
This trial tests a combination of chemotherapy (mFOLFOX7) plus two targeted/immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer that has grown beyond standard transplant criteria. It aims to shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06516289RecruitingPhase 2
Neoadjuvant treatment for BRCA-mutated HER2-negative breast cancer
This trial tests a combination of two oral medications (HRS-1167 and famitinib) with or without an immunotherapy drug (camrelizumab) before surgery for women with a BRCA gene mutation and HER2-negative breast cancer. It aims to see if these drugs can shrink tumors before surgery.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05576389RecruitingPhase 2
Fluzoparib plus camrelizumab before surgery for BRCA-related HER2-negative breast cancer
This study tests a combination of two drugs – fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy) – given before surgery for early-stage or locally advanced HER2-negative breast cancer in people with an inherited BRCA mutation. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Camrelizumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for camrelizumab?
- Yes. Clin2 currently lists 109 recruiting camrelizumab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a camrelizumab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a camrelizumab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.